Document Detail


Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study.
MedLine Citation:
PMID:  23303471     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: Methamphetamine is associated with psychotic phenomena, but it is not clear to what extent this relationship is due to premorbid psychosis among people who use the drug.
OBJECTIVE: To determine the change in the probability of psychotic symptoms occurring during periods of methamphetamine use.
DESIGN: Longitudinal prospective cohort study. A fixed-effects analysis of longitudinal panel data, consisting of 4 noncontiguous 1-month observation periods, was used to examine the relationship between changes in methamphetamine use and the risk of experiencing psychotic symptoms within individuals over time.
SETTING: Sydney and Brisbane, Australia.
PARTICIPANTS: A total of 278 participants 16 years of age or older who met DSM-IV criteria for methamphetamine dependence on entry to the study but who did not meet DSM-IV criteria for lifetime schizophrenia or mania.
MAIN OUTCOME MEASURES: Clinically significant psychotic symptoms in the past month, defined as a score of 4 or more on any of the Brief Psychiatric Rating Scale items of suspiciousness, hallucinations, or unusual thought content. The number of days of methamphetamine use in the past month was assessed using the Opiate Treatment Index.
RESULTS: There was a 5-fold increase in the likelihood of psychotic symptoms during periods of methamphetamine use relative to periods of no use (odds ratio [OR], 5.3 [95% CI, 3.4-8.3]; P < .001), this increase being strongly dose-dependent (1-15 days of methamphetamine use vs abstinence in the past month: OR, 4.0 [95% CI, 2.5-6.5]; ≥16 days of methamphetamine use vs abstinence in the past month: OR, 11.2 [95% CI, 5.9-21.1]). Frequent cannabis and/or alcohol use (≥16 days of use in the past month) further increased the odds of psychotic symptoms (cannabis: OR, 2.0 [95% CI, 1.1-3.5]; alcohol: OR, 2.1 [95% CI, 1.1-4.2]).
CONCLUSIONS: There was a large dose-dependent increase in the occurrence of psychotic symptoms during periods of methamphetamine use among users of the drug.
Authors:
Rebecca McKetin; Dan I Lubman; Amanda L Baker; Sharon Dawe; Robert L Ali
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  JAMA psychiatry     Volume:  70     ISSN:  2168-6238     ISO Abbreviation:  JAMA Psychiatry     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-03-07     Completed Date:  2013-05-02     Revised Date:  2013-12-13    
Medline Journal Info:
Nlm Unique ID:  101589550     Medline TA:  JAMA Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  319-24     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Alcohol Drinking / adverse effects,  epidemiology
Amphetamine-Related Disorders / epidemiology*
Australia / epidemiology
Central Nervous System Stimulants / adverse effects*
Cohort Studies
Dose-Response Relationship, Drug
Female
Humans
Longitudinal Studies
Male
Marijuana Smoking / adverse effects,  epidemiology
Methamphetamine / adverse effects*
Odds Ratio
Prospective Studies
Psychoses, Substance-Induced / epidemiology*
Psychotic Disorders / epidemiology*
Risk Factors
Chemical
Reg. No./Substance:
0/Central Nervous System Stimulants; 44RAL3456C/Methamphetamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sotalol as first line treatment in fetal tachycardias and neonatal follow-up.
Next Document:  Molecular characteristics of a pancreatic adenocarcinoma associated with Shwachman-Diamond syndrome.